Mark Lauer is a notable inventor based in Olmsted Falls, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammation. With a total of 2 patents, Lauer's work focuses on innovative compositions that aim to improve health outcomes.

Latest Patents

Lauer's latest patents include a groundbreaking pharmaceutical composition designed to treat the extracellular matrix to reduce inflammation. This composition comprises a compound featuring a hyaluronan-containing structure A-(low molecular weight hyaluronan domain)-B. The formulation includes a pharmaceutically acceptable excipient, where A is hydrogen or a substituent that does not comprise a binding site for tumor necrosis factor stimulated gene-6 ('TSG-6') protein. B is hydroxyl or a substituent that also does not comprise a binding site for TSG-6 protein. The composition is versatile, suitable for administration by injection, inhalation, topical rub, or ingestion. Additionally, methods and kits for treating inflammation and decreasing heavy chain modification of pathological hyaluronan are disclosed.

Career Highlights

Mark Lauer is affiliated with the Cleveland Clinic Foundation, where he continues to advance his research and innovations in the pharmaceutical field. His work is characterized by a commitment to developing effective treatments for inflammation, showcasing his dedication to improving patient care.

Collaborations

Lauer has collaborated with esteemed colleagues such as Vincent Hascall and Anthony Calabro, contributing to a rich environment of innovation and research.

Conclusion

Mark Lauer's contributions to pharmaceutical compositions highlight his role as an innovator in the field. His patents reflect a commitment to addressing critical health issues through scientific advancements.